Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1997, Onyvax is a private biotechnology company developing novel cancer therapies that harness the selective power of the immune system to seek and destroy tumour cells. Onyvax' products specifically target cancer cells, increasing the likelihood that they will be effective, while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.